Comparative Pharmacology
Head-to-head clinical analysis: NEOMYCIN SULFATE TRIAMCINOLONE ACETONIDE versus OTICAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOMYCIN SULFATE TRIAMCINOLONE ACETONIDE versus OTICAIR.
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE vs OTICAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Triamcinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins, thereby decreasing prostaglandin and leukotriene synthesis, and exerts anti-inflammatory, antipruritic, and vasoconstrictive effects.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication; fluocinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins, reducing prostaglandin and leukotriene synthesis, thereby suppressing inflammation.
Topical: Apply thin film to affected area 2-4 times daily. Otic: Instill 3-4 drops into ear canal 2-3 times daily. Not for systemic use.
1-2 sprays into each affected ear twice daily for 7 days. Topical route.
None Documented
None Documented
Neomycin: 2-3 hours (normal renal function); in renal impairment, prolonged up to 12-24 hours. Triamcinolone acetonide: 2-5 hours (terminal).
4.2 hours; prolonged in renal impairment (up to 12 hours in creatinine clearance <30 mL/min)
Neomycin: >90% orally administered excreted unchanged in feces; absorbed fraction (3-6%) excreted renally with 50% within 24 hours. Triamcinolone acetonide: primarily hepatic metabolism, renal excretion of metabolites (~40% as 11-keto derivatives), fecal excretion ~20%.
Renal: 85% unchanged; biliary/fecal: 10%
Category D/X
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid